Azvudine for the treatment of cancer patients with COVID-19: a multicenter, real-world, retrospective, cohort study.

BMC Cancer · 2026 · PMC13067604 · PMID 41776490

Europe PMC DOI

hedged sentences

0.0510

closest p · 1.0× alpha

0.0640

boldest claim

The sentences

a strong trendP = 0.051so close (0.05 < p ≤ 0.1)

regarding composite disease progression, the Kaplan-Meier curves showed a strong trend toward risk reduction in the Azvudine group (Log-rank P = 0.051, Figure S2B).

also in 3,343 other papers

a trend toward significanceP = 0.064so close (0.05 < p ≤ 0.1)

According to the Kaplan-Meier analysis, the cumulative incidence of disease progression was lower in the Azvudine group, showing a trend toward significance (Log-rank P = 0.064) (Fig. 2 B).

also in 2,499 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.